Lipoprotein(a) and the cardiovascular drug frontier — the emerging recognition of elevated Lp(a) as a genetically determined independent cardiovascular risk factor affecting approximately twenty percent of the global population — combined with the clinical development of multiple agents specifically targeting Lp(a) reduction — creating what may become the next major...